Vulnerability in Insulet Omnipod Insulin Management System
CVE-2020-10627
Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
EPSS: 0.005 (38.6th percentile) — read the EPSS interpretation.
CVSS v3 metric
CVSS v3 base score 7.3 (High). Vector: CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:L.
Affected products
- Insulet Omnipod Insulin Management System — versions 19191, 40160, ZXP425
- Insulet Omnipod_insulin_management_system — versions 19191, 40160
- Insulet Omnipod_insulin_management_system_firmware
Weakness classification (CWE)
Public proof-of-concept exploits
References
- ics-cert@hq.dhs.gov (US Government Resource, Third Party Advisory, x_refsource_MISC)
- ics-cert@hq.dhs.gov (x_refsource_MISC, Vendor Advisory)
Frequently asked questions
- What is CVE-2020-10627?
- CVE-2020-10627 is a high-severity vulnerability in Insulet Omnipod Insulin Management System, classified under Improper Access Control. CVSS score: 7.3/10. Published 2021-12-01.
- How severe is CVE-2020-10627?
- High severity. CVSS v3 base score is 7.3 out of 10.
- Is CVE-2020-10627 known to be exploited?
- 1 public proof-of-concept repositories are indexed. Not currently listed in the CISA KEV catalog.